Stock Dives 28%
Oxigene Restructures, Future of Lung Cancer Drug Uncertain
By Catherine Shaffer
Friday, September 2, 2011
Oxigene Inc. reported a radical restructuring to conserve resources and focus on earlier stage programs. The company will conclude its Phase II trial of Zybrestat in non-small-cell lung cancer (NSCLC), and defer initiation of Phase III registration studies of the drug in anaplastic thyroid cancer due to lack of funding.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.